Topic: DDOX

Previous tetracycline (TC) studies hinted at its analgesic potential. We explored here it in new non-antibiotic TC derivatives. Using the formalin-induced nociceptive pain model in male adult C57⁄BL6 mice, we tested the effects of DDMC (5, 10, 20 mg.kg-1) and DDOX (10, 20, 40 mg.kg-1), non-antibiotic derivatives of demeclocycline and doxycycline, respectively. A sub-chronic treatment with 5 mg.kg-1 of DDMC remarkably reduced nociceptive pain in both phases of the test, comparable to morphine (10 mg.kg-1). DDOX was also effective but intrinsically less potent than DDMC as exerting analgesic eff

Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of substantia nigra dopaminergic neurons, leading to dopaminergic deafferentation of the striatum and invalidating motor symptoms. Several studies suggest that doxycycline (DOX), an old antibiotic from the tetracycline family, could be a neuroprotective drug candidate for PD (Bortolanza et al, J Neural Transm, 2018). Its antibiotic activity may, however, preclude chronic use in patients. Therefore, we have developed a non-antibiotic derivative of DOX referred to as DDOX (12a-deoxy-dedimethylamino-DOX),